{"id":182004,"date":"2026-07-02T11:22:42","date_gmt":"2026-07-02T09:22:42","guid":{"rendered":"https:\/\/www.startupbusiness.it\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/"},"modified":"2026-07-03T09:27:03","modified_gmt":"2026-07-03T07:27:03","slug":"creadd-ventures-aims-to-raise-100-million-swiss-francs","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/","title":{"rendered":"Creadd Ventures aims to raise 100 million Swiss francs"},"content":{"rendered":"\n

The fundraising campaign for Creadd 2, the second fund from Swiss venture capital firm Creadd Ventures, has officially begun with the ambitious target of raising 100 million Swiss francs. <\/p>\n\n

The strategy reflects the growth of the portfolio companies and the need to support increasingly substantial funding rounds, notes Lorenzo Leoni, co-founder of Creadd alongside Paolo Orsatti.<\/p>\n\n

The first phase involves the commitment of around 25 million Swiss francs from established investors with extensive experience, whilst the second \u2013 scheduled for next year \u2013 will open the door to family offices and other European and Asian limited partners.<\/p>\n\n

Creadd is open to considering proposals from partners capable of supporting the international roadshow and building trust with investors who do not yet have a direct relationship with the team.<\/p>\n\n

Placement agents can play a key role in expanding the LP base, particularly in markets such as Singapore and Japan, where Creadd already has strong contacts, as well as in Hong Kong.<\/p>\n\n

The aim of Creadd 2 is to build a portfolio of 12\u201315 companies with an 8+2 structure: an eight-year standard term for the vehicle to invest in, manage and develop its holdings, plus a two-year optional extension.<\/p>\n\n

The investment is made over three to four years via capital calls, with initial investments ranging from one million to five million Swiss francs and a 50 per cent reserve for follow-on investments. Exposure to any single company is limited to 15 per cent of the capital. <\/p>\n\n

The sector allocation strategy provides for a balanced distribution: 35%\u201345% in life sciences and medtech, 35%\u201345% in deep tech, and 20%\u201330% in AI and B2B SaaS solutions. This structured approach ensures diversification, scalability and the protection of pro-rata rights. <\/p>\n\n

The main characters<\/strong><\/h2>\n\n

Lorenzo Leoni and Paolo Orsatti are the founders of Creadd, a fund with deep roots in the technology ecosystem of the Canton of Ticino.<\/p>\n\n

\"\"
Lorenzo Leoni (left) and Paolo Orsatti, managing partner at Creadd Ventures<\/figcaption><\/figure>\n\n

Leoni, a serial entrepreneur and venture capitalist, has built his reputation in the biotech sector across the United States and Europe, bringing with him a wealth of experience that is now reflected in the healthcare companies within the fund\u2019s portfolio. His vision is to identify companies with solid intellectual property and significant clinical potential, capable of transforming research into tangible healthcare solutions. <\/p>\n\n

Alongside him, Orsatti brings an industrial background rooted in the world of semiconductors and telecommunications, having developed in-depth expertise in hardware and industrial technologies. It is thanks to this perspective that Creadd has developed a second strand of expertise \u2013 that of deep tech \u2013 capable of harnessing innovations in automation, components and advanced systems. <\/p>\n\n

The complementary nature of Leoni and Orsatti is one of the fund\u2019s key strengths: two distinct verticals, both of which are rooted in technology-intensive sectors with defensible barriers. This synergy enables Creadd to navigate confidently between biotech and industrial technologies, integrating AI as an enabling technology whilst maintaining a strategic coherence that has already yielded tangible results. <\/p>\n\n

Leoni and Orsatti also manage TiVentures, an evergreen institutional fund established in 2016 under the auspices of the BancaStato Centenary Foundation, which invests exclusively in start-ups based in the Canton of Ticino. <\/strong>With average investment amounts of around CHF 500,000 Swiss francs and pre-investment valuations of between 3 and 5 million Swiss francs, it has backed around 25 companies over the past ten years and has now reached the \u2018harvesting\u2019 stage of its portfolio.<\/p>\n\n

Creadd Ventures, on the other hand, is a private firm focused on scale-ups with no geographical restrictions. With a portfolio of 7\u20138 companies, it raised 12 million Swiss francs between late 2023 and 2025, almost all of which has been allocated. Its role is to provide continuity for TiVentures\u2019 investments, supporting the companies towards funding rounds of 30\u201340 million Swiss francs alongside leading co-investors such as United Ventures, Swisscom Ventures, Emerald and Partech. <\/p>\n\n

The investment thesis<\/strong><\/h2>\n\n

The investment philosophy of TiVentures and Creadd Ventures focuses on technology-intensive sectors, where intellectual property and defensible know-how represent a genuine competitive advantage.<\/p>\n\n

The focus is primarily on healthcare \u2013 biotech, medtech and digital health solutions \u2013 and on industrial technologies, which are now often grouped under the umbrella term \u2018deep tech\u2019: semiconductors, telecommunications, automation and advanced hardware.<\/p>\n\n

Artificial intelligence is not regarded as a standalone sector, but rather as an enabling technology that must be integrated into B2B or SaaS applications related to these two main areas.<\/p>\n\n

One of the most significant achievements is that of Gain Therapeutics, which was listed on the Nasdaq in less than four years. The company recently published encouraging Phase 2 data on Parkinson\u2019s disease, with a potential first-in-class drug capable of transforming the management of the condition. In addition to the financial return, this case represents a highly significant clinical validation. <\/p>\n\n

Another example is xFarm,<\/a> a digital agriculture company that has grown to over 200 employees and operates in Europe and Brazil. Founded with the support of TiVentures and subsequently backed by Creadd, it is now one of the global leaders in the sector and is actively pursuing acquisitions.<\/p>\n\n

Finally, Delvitech stands out for its optical inspection systems for electronic circuits, with a strong presence in India and prospects for industrial validation in the short term. These three cases illustrate the typical path taken by the funds: entry at the early stages with TiVentures, continuity and scale-up with Creadd, leading to results of international significance.<\/p>\n\n

An evolving ecosystem<\/strong><\/h2>\n\n

Switzerland has been at the forefront of global innovation for 14 consecutive years, thanks to centres such as ETH Zurich and EPFL, which have generated over 660 spin-offs with a survival rate of 93 per cent and a combined value of more than 50 billion dollars.<\/p>\n\n

Despite this robust pipeline, a structural capital gap persists. The number of Series A funding rounds has fallen, although they have reached record volumes, with increasingly high investment amounts that are posing challenges for local funds. <\/p>\n\n

The synergy between institutional and private funds creates a continuum that reduces risk in the early stages and supports growth in the later stages. In the absence of major public investors such as Cassa Depositi e Prestiti (CDP), Bpifrance or the European Investment Fund (EIF), the Swiss model is to grow organically, \u201ca bit like start-ups\u201d, notes Leoni.<\/strong><\/p>\n\n

With Creadd 2, the challenge will be to scale up further, whilst maintaining investor confidence and the quality of the portfolio. The priority is to consolidate the initial commitments, before expanding to a global audience. The network of relationships in Asia \u2013 spanning Singapore, Japan and Hong Kong \u2013 provides a natural bridge to international markets and capital. <\/p>\n\n

The raising of 100 million Swiss francs marks a significant step forward for Creadd Ventures and for the entire Swiss ecosystem, which is now ready to compete on a global scale with larger funds.<\/p>\n\n

More than half of Swiss venture capital firms manage less than 50 million Swiss francs and lack the capacity to support growth rounds; however, the fact that new rounds of 60\u201370 million Swiss francs are currently underway confirms that Swiss venture capital firms are entering a new phase of maturity.<\/p>\n\n

However, this is still not enough. Pan-European mega-funds, which lack deep-tech expertise, only come on board from Series B onwards, providing 96 per cent of late-stage capital. With this new fund, Creadd Ventures aims to fill this gap by acquiring controlling stakes as early as the commercial validation stage, before the arrival of major international investors. <\/p>\n","protected":false},"excerpt":{"rendered":"

The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase<\/p>\n","protected":false},"author":125,"featured_media":182002,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"_substack_draft_id":"","_substack_draft_url":"","_substack_last_pushed":"","_substack_premium":"","footnotes":""},"categories":[1142],"tags":[1330,2236,1321,1323],"companies":[3567],"journalist":[3379],"class_list":["post-182004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vc-voice","tag-deeptech-en","tag-europa-en","tag-lifescience-en","tag-scaleup-en","companies-creadd-ventures","journalist-riccardo-ghia"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","width":150,"height":78,"crop":false,"srcset":false,"alt":"Swiss venture capital"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","width":1024,"height":535,"crop":false,"srcset":false,"alt":"Swiss venture capital"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","width":1333,"height":697,"crop":false,"srcset":false,"alt":"Swiss venture capital"}},"acf":[],"yoast_head":"\nCreadd Ventures aims to raise 100 million Swiss francs<\/title>\n<meta name=\"description\" content=\"The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Creadd Ventures aims to raise 100 million Swiss francs\" \/>\n<meta property=\"og:description\" content=\"The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-02T09:22:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-03T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1333\" \/>\n\t<meta property=\"og:image:height\" content=\"697\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Creadd Ventures aims to raise 100 million Swiss francs\",\"datePublished\":\"2026-07-02T09:22:42+00:00\",\"dateModified\":\"2026-07-03T07:27:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/\"},\"wordCount\":1210,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg\",\"keywords\":[\"deeptech\",\"Europa\",\"lifescience\",\"Scaleup\"],\"articleSection\":[\"Vc Voice\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/\",\"name\":\"Creadd Ventures aims to raise 100 million Swiss francs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg\",\"datePublished\":\"2026-07-02T09:22:42+00:00\",\"dateModified\":\"2026-07-03T07:27:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/creadd-ventures-aims-to-raise-100-million-swiss-francs\\\/182004\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg\",\"width\":1333,\"height\":697,\"caption\":\"Swiss venture capital\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac925fb049ca749d7e16a36a75fbc9bf342bb19b7c22dae55be274ab4557890a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac925fb049ca749d7e16a36a75fbc9bf342bb19b7c22dae55be274ab4557890a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac925fb049ca749d7e16a36a75fbc9bf342bb19b7c22dae55be274ab4557890a?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Creadd Ventures aims to raise 100 million Swiss francs","description":"The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/","og_locale":"en_US","og_type":"article","og_title":"Creadd Ventures aims to raise 100 million Swiss francs","og_description":"The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase","og_url":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/","og_site_name":"Startupbusiness.it","article_published_time":"2026-07-02T09:22:42+00:00","article_modified_time":"2026-07-03T07:27:03+00:00","og_image":[{"width":1333,"height":697,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","type":"image\/jpeg"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Creadd Ventures aims to raise 100 million Swiss francs","datePublished":"2026-07-02T09:22:42+00:00","dateModified":"2026-07-03T07:27:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/"},"wordCount":1210,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","keywords":["deeptech","Europa","lifescience","Scaleup"],"articleSection":["Vc Voice"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/","url":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/","name":"Creadd Ventures aims to raise 100 million Swiss francs","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","datePublished":"2026-07-02T09:22:42+00:00","dateModified":"2026-07-03T07:27:03+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"The fund, based in the Canton of Ticino, aims to invest in life sciences and deep tech start-ups in their growth phase","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/creadd-ventures-aims-to-raise-100-million-swiss-francs\/182004\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/07\/1.4_March-19-2021_Gain-Therapeutics-raised-USD-46m-through-Nasdaq-listing.jpg","width":1333,"height":697,"caption":"Swiss venture capital"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ac925fb049ca749d7e16a36a75fbc9bf342bb19b7c22dae55be274ab4557890a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ac925fb049ca749d7e16a36a75fbc9bf342bb19b7c22dae55be274ab4557890a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ac925fb049ca749d7e16a36a75fbc9bf342bb19b7c22dae55be274ab4557890a?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Vc Voice"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/182004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=182004"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/182004\/revisions"}],"predecessor-version":[{"id":182005,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/182004\/revisions\/182005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/182002"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=182004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=182004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=182004"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=182004"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=182004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}